Physician profile
Rafael E Llanso
NPI 1659305589
$2,928.55
in general payments reported to CMS, 2019-2025
23 companies · $794 in 2025
The $794 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $207 · 2021: $237 · 2022: $372 · 2023: $573 · 2024: $410 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $441.80 | 2019-2025 | Pediarix, Bexsero, Rotarix |
| Pfizer INC. | $389.27 | 2019-2025 | |
| Corium, LLC | $384.62 | 2021-2025 | Azstarys |
| Sanofi Pasteur INC. | $253.47 | 2019-2025 | |
| Cranial Technologies, INC | $228.35 | 2019-2025 | Doc Band |
| Regeneron Healthcare Solutions, INC. | $216.20 | 2025 | Dupixent |
| Ironshore Pharmaceuticals INC. | $166.48 | 2019-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $162.13 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $141.24 | 2020-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Tris Pharma INC | $120.34 | 2019-2022 | |
| Neos Therapeutics, Lp | $85.20 | 2019-2024 | Adzenys Xr-Odt |
| Seqirus USA INC | $83.16 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $52.86 | 2021 | |
| Abbvie INC. | $28.42 | 2022 | |
| Verrica Pharmaceuticals INC. | $27.08 | 2024 | Ycanth |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $25.00 | 2025 | Zelsuvmi |
| Adlon Therapeutics L.P. | $21.56 | 2019 | |
| Vertical Pharmaceuticals, LLC | $20.36 | 2020 | |
| Collegium Pharmaceutical, INC. | $20.00 | 2025 | Jornay Pm |
| Shire North American Group INC | $16.00 | 2019 | |
| Genentech USA, INC. | $15.52 | 2020 | |
| Phadia US INC. | $15.49 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Llanso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.